• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Elacestrant: Adverse Effects and Their Management, and Impact of Treatment on Quality of Life

Opinion
Video

Experts discuss the impact of elacestrant on patient well-being, including potential cardiovascular and gastrointestinal toxicities, quality of life, and patient feedback regarding access to treatment.

This is a video synopsis/summary of a Peer Exchange featuring Mabel Mardones, MD; Rena Callahan, MD; William Gradishar, MD; and Gregory Vidal, MD, PhD.

Mardones discusses toxicities associated with oral selective estrogen receptor degraders (SERDs) with Vidal, Callahan, and Gradishar. Vidal addresses cardiovascular, reproductive, and bone health, noting potential toxicities in some oral SERDs but emphasizing their overall well-tolerated nature and how they provide clinicians with effective alternatives to chemotherapy. Callahan delves into nausea and gastrointestinal toxicities, citing a learning curve and advising patients to take the drug with food to minimize adverse effects. The patient-reported outcomes data presented at the 2023 European Society for Medical Oncology Congress suggests an improvement in patient-reported nausea and vomiting, enhancing the overall experience. Gradishar emphasizes that oral SERDs, particularly elacestrant, maintain quality of life with minimal adverse effects and improved tolerability compared with chemotherapy. Vidal highlights the evolving landscape of prior authorization, acknowledging initial challenges but noting improved processes, voucher programs, and timely access to drugs, which streamlines the patient experience. This discussion offers a comprehensive view of the toxicities associated with oral SERDs and insights into managing patient experiences in clinical practice.

Video synopsis is AI-generated and reviewed by AJMC® editorial staff.

Related Videos
Ronesh Sinha, MD
Yuqian Liu, PharmD
Video 11 - "Social Burden and Goals of Therapy for Patients with Bronchiectasis"
Video 7 - "Harnessing Continuous Glucose Monitors for Type 1 Diabetes Management + Closing Words"
dr monica li
dr lawrence eichenfield
Video 14 - "Achieving Equitable Representation in Clinical Studies"
Video 13 - "Measuring Implicit Bias"
Dr Michael Morse, Duke University
Video 10 - "Bronchiectasis Exacerbation Management"
Related Content
© 2024 MJH Life Sciences
AJMC®
All rights reserved.